Nico Callewaert
Tuesday 2nd July 2024, 14:45-15:45
Cell surface glycosylation engineering of CAR-T cells.
Nico is professor of biochemistry and biotechnology at Ghent University and scientific director for VIB’s Center for Medical Biotechnology, in which 125 scientists in 8 research groups work to innovate biomedical molecular analytics and bio-engineering. His lab develops biomedical analytical technology for diagnostics and target discovery, as well as synthetic biotechnology for customized biopharmaceutical molecule- and cell engineering. While the lab focuses on innovating the foundations of technology in these areas, practical end-products of our endeavors include GlycoLiverProfile for cirrhosis diagnosis and HCC risk assessment, now being introduced in the clinic (Helena-biosciences.com), lysosome-drug targeting glyco-engineering (oxyrane.com), yeast GlycoSwitch glycan humanization and GlycoDelete biopharmaceutical glyco-engineering, orally administered antibody technology for GI tract disease treatment (animab.com) and VHH-Fc anti-infectious disease antibodies, incl. XVR011 for Covid19 (exevir.com). Nico is an inventor of more than 200 patent applications in >35 different families.
Visit us on Social Media
#ECB2024
Please note: All information requested on the website and registration process is strictly for the use of the Congress in compliance with international privacy legislation. By completing this registration form you will agree that the Congress will use this data to keep you fully informed of the Congress in 2024. The data will then be retained by the Congress secretariat for the purposes of informing you about activities and future meetings. On the registration form, You will also have the opportunity to agree separately to allow key data (Name, Company, Email Address) to be shared with sponsors and exhibitors who are participating in the Congress in 2024. We will not pass any details to any companies not participating in the Congress in 2024.